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(≥50yrs), herpes zoster (≥50yrs), and pertussis (≥18yrs) made up 51%, 30%, 16%, 
and 3% of the cost, respectively. Among those aged ≥50 years, influenza, 
pneumococcal disease, herpes zoster, and pertussis made up 31%, 44%, 24%, and 
1% of the cost, respectively. Most (82%) pneumococcal costs stemmed from non-
bacteremic pneumococcal pneumonia (NPP). Direct medical costs accounted for 
91% of total pneumococcal burden, but only 27%, 28%, and 42% of total economic 
burden due to influenza, herpese zoster, and pertussis, respectively. Sensitivity 
analysis revealed that estimated influenza rates and costs per case, NPP 
incidence and directs costs, and herpes zoster incidence rates and indirect costs 
impacted the model most. CONCLUSIONS: Cost attributable to adult VPD in the 
United States is substantial. Broadening adult immunization efforts beyond 
influenza only may help reduce the economic burden of adult VPD, and a 
pneumococcal vaccination effort, primarily focused on reducing NPP, may be a 
logical place to start.  
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OBJECTIVES: To determine the epidemiologic and economic burdens  
of tuberculosis (TB) in Asia. METHODS: A systematically review of primary 
studies in Asia was conducted. We searched MEDLINE, PUBMED, EMBASE, 
Science Direct, CNKI from January 1, 2000 to July 15, 2012; and websites of 
relevant countries and international organizations. RESULTS: TB prevalence, 
incidence and mortality in the region have declined since 1990 and status relate 
to the economy of the country. In 2010, there were 8.8 million incident cases of 
TB (128/100000 population). Most of the cases occurred in Asia (59%) and Africa 
(26%). India and China accounted for 40% of new and relapse TB cases. In 2006, 
TB caused India to lose a 23.7 billion US$. The mean direct cost was US$34.9  
and mean indirect cost was $526.9. The total cost per patient was $562.7. In 
China, low income patients paid $149 to $724 for medical costs for a treatment 
course (42% to 119% of annual household income). In Philippines, the economic 
losses totaled PhP8 billion (US$145 million) and costs of treating all cases 
requires PhP475–1625 million (US$8–29 million) annually. In Cambodia, TB is the 
second largest cause of mortality. Monthly household costs were US$124/ 
patients ($135 for TB-HIV patients and $260 for resistant-TB patients); the 
average monthly income in Cambodia is $168. In Tajikistan, Patients and their 
households faced mean expenditures of US$ 396; (median US$ 282) related to a 
TB episode. CONCLUSIONS: Although most countries in Asia have done many 
efforts on TB control, the absolute number of patient is large that more efforts 
need to take to achieve the goal of 50% reduction in 2015 from 1990 set by WHO. 
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OBJECTIVES: To describe the cost of outbreak of meningococcal disease in 
Cartagena - Colombia. METHODS: The cost of meningococcal disease outbreak 
from February 21st thru March 21st2012, were described. The suspected cases 
were detected in the Children´s Hospital Napoleon Franco Pareja, House of the 
Child (HC) and they were reported to the Departamento Administrativo Distrital 
de Salud (DADIS, for acronym in Spanish). We ran an active surveillance program 
in the neighborhood cases. The investigation costs of the outbreak control, 
surveillance and health care cost were estimated. RESULTS: During 
meningococcal disease outbreak and following 1 month of active surveillance, a 
total of 6 cases were detected; from which one suspected case, one probable case 
and four were confirmed cases. The average patient age was 4.6 years. 50% of the 
cases died, 33% of the cases had meningitis, meningococcemia and myocarditis. 
66% of the cases had culture specimen positive with Neisseria meningitidis. 5/6 
cases (83%) had RT-PCR positive with Neisseria meningitidis. All N. meningitidiswere 
serogroup B. 50 doses of ceftriaxone were administered as prophylaxis. DADIS 
did not recommend meningococcal vaccination and the proper vaccine was not 
available at the time. The costs of meningococcal outbreak were estimated as 
follows: Cost of control of the outbreak (US $ 735), disease surveillance phase (US 
$ 3,935) and health care cost was US $ 4.670. CONCLUSIONS: All cases were 
caused by N. meningitidis serogroup B. The absence of vaccination involves lower 
costs in control of the outbreak.  
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OBJECTIVES: Patients with COPD are at increased risk for lung infections, such as 
pneumonia. However, few studies have evaluated the impact of pneumonia on 
health care resource utilization (HCRU) and cost in this population. The objective 
of this study is to estimate HCRU and cost in COPD patients with newly acquired 
pneumonia, compared to those without pneumonia. METHODS: A retrospective 
analysis using MarketScan® Commercial Claims and Encounters and Medicare 
Supplemental Databases was conducted. COPD patients with and without newly 
diagnosed pneumonia between January 1, 2005 and September 30, 2010 were 
identified. Propensity score matching was used to create a one-to-one matched 
cohort. Patient demographics, comorbidities measured by Charleston 
Comorbidity Index (CCI), and medication use were evaluated before and after 
matching. HCRU, including the number of hospitalizations, emergency room 
(ER), and outpatient visits, length of hospital stay (LOS), and associated health 
care costs were assessed during the 12-month follow up. Two-part models and 
gamma regression models were conducted to compare costs between groups 
after matching. RESULTS: In the baseline cohort of 520,008 patients, newly 
acquired pneumonia patients were older (mean age: 70 vs. 63 years) and sicker 
(CCI: 3.25 vs. 2.67). After matching, no baseline covariates were statistically 
different between groups. In the matched cohort of 168,260 patients, one-year 
mean HCRU after pneumonia onset was significantly higher (all p<0.0001) for 
inpatient visits (1.2 vs. 0.29), ER visits (1.9 vs. 0.68), outpatient visits (34.97 vs. 
23.1) and LOS (7.3 vs. 1.3 days) than the control cohort. Estimated one-year mean 
costs were higher in the pneumonia cohort with differences in: inpatient costs 
$14,353 (95% CI: $14,037, $14,690), outpatient costs $6,891 ($6,706, $7,075), 
prescription drug costs $1,104 ($1,054, $1,152) and total costs $23362 ($22,969, 
$23,787). CONCLUSIONS: Our study demonstrates elevated HCRU and costs in 
COPD patients after acquiring pneumonia.  
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OBJECTIVES: The cost of antibiotics is always an area of concern in treating RTI. 
The purpose of the current study was to determine the contribution of costs of 
antibiotics on the overall prescription costs in paediatric patients. METHODS: 
The study was carried out at a pediatric outpatient setting where data of 688 
patients, below 18 years of age, was captured over a period of one year from the 
“Wise-kid” software. RESULTS: RTI was most common in the age group of 1-3 Y 
(32%) and 3-6 Y (30%). It affects the patients mostly in winter (35%) followed by 
autumn (25%). Antibiotic prescribed from NLEM-2011 were found to be 92%. All 
the antibiotics were prescribed by oral route with brand name only. Percentage 
of encounters with antibiotics in RTI, were highest in acute otitis media (AOM, 
89%), followed by lower respiratory tract illness (LRTI, 76%), tonsillitis (71%), 
upper respiratory tract infection (URTI) + bronchospasm (17%), URTI (13%) and 
influenza like illness (ILI, 13%). The average cost of treatment was maximum for 
AOM (INR186±7; 1USD=approx INR55) followed by LRTI, ILI, URTI (181±11, 125±6 
& 120±2, respectively in INR). While the average cost spent on antibiotic 
treatment was INR 82±8. Of total cost, 17% was spent on the utilization of 
antibiotics.The order for cost spent on use of different class of drug were cold & 
cough combinations (37%) > NSAIDs (9%) > nasal drops. The contribution of 
antiasthmatics, antihistamines & antibiotics was found to be 6% each. Among 
antibiotics, maximum cost were spent on the use of amoxicillin+clavulanic acid 
combination (66%) followed by the cost spent on the prescribing of azithromycin, 
cefpodoxime, clarithromycin, cephalexin & ofloxacin (24%, 4%, 4%, 1.5% & 1% 
respectively). CONCLUSIONS: The results indicate that less than 20% costs were 
spent on antibiotics for the treatment of RTI. These results build the evidence for 
the cost of treating RTI in children.  
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OBJECTIVES: To evaluate the occurrence and associated health care utilization 
and costs of potential adverse events (AEs) associated with outpatient 
voriconazole use among patients with aspergillosis. METHODS: Commercially-
insured adults aged ≥18 years with at least one medical claim with a diagnosis  
of aspergillosis (ICD-9-CM 117.3 or 484.6) between July 1, 2004-March 1, 2011 and 
outpatient voriconazole treatment on or after the index diagnosis were identified 
from the MarketScan Research Databases. Patients were required to have ≥6 
months of pre-index and ≥1 month of post-index health plan and pharmacy 
benefit enrollment. Patients with an aspergillosis diagnosis in the pre-index 
period were excluded. Potential AEs, as indicated in the package insert  
for voriconazole, were identified via diagnosis codes and were evaluated for 
periods during active treatment plus 7 days. AE-related monitoring , such as 
organ function tests and visits with ophthalmologists, were also evaluated. Total 
all-cause costs and potential AE-related costs were calculated. RESULTS: A total 
of 1511 patients treated with voriconazole were identified. The most common 
conditions observed during active treatment with voriconazole plus 7 days were 
fever (15.1%), tachycardia (12.2%), acute kidney failure (8.9%), and 
nausea/vomiting (8.4%). AE-related inpatient admissions and outpatient 
physician office visits were observed for 19.9% and 40.8% of patients, 
respectively. Outpatient AE-related organ function testing, aspergillosis-related 
laboratory tests, including therapeutic drug monitoring, and at least one office 
visit with an ophthalmologist, was observed among 16.3%, 34.5%, 18.1%  
of patients, respectively. Average total, aspergillosis-related costs during follow-
up of patients treated with voriconazole were $35,968 ± $68,590. Average total 
costs associated with adverse events and adverse event monitoring were $3,772 
± $30,057 or 10.5% of total average costs. CONCLUSIONS: Conditions suggestive 
of AEs associated with voriconazole occurred frequently, and were associated 
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with notable resource utilization, including inpatient admissions. Average total 
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OBJECTIVES: To assess the clinical characteristics and economic burden of 
patients diagnosed with the hepatitis C virus (HCV) in the U.S. veteran 
population. METHODS: A retrospective database analysis was performed using 
the Veterans Health Administration (VHA) Medical SAS Datasets from October 1, 
2005 to May 31, 2012. All U.S. veteran beneficiaries diagnosed with HCV were 
identified using International Classification of Disease 9th Revision Clinical 
Modification (ICD-9-CM) diagnosis codes 070.41, 070.44, 070.51, 070.54, and 
V02.62. Comorbidities and other clinical conditions were assessed for the 12-
month baseline period. Health care resource utilization and costs were assessed 
for the 12-month follow-up period. Descriptive statistics were calculated as 
means ± standard deviation (SD) and percentages to measure cost, and 
utilization distribution in the sample. RESULTS: A total of 146,161 veterans were 
diagnosed with HCV during the study period. Among the 10 most common 
baseline comorbidities, hypertension was the only condition comprising of more 
than 20% of patients. Patients were also diagnosed with comorbid lumbago 
(8.26%), presbyopia (3.93%) and backache (3.80%), which are common in the 
elderly population. During the baseline period, 4172 patients (or approximately 
3% of the patient population) had Albumin test results of <3.0 mg/dl. 15.03% of 
patients had Prolonged Prothrombin Time Test results of >3.0 seconds. 
Omeprazole (16.06%), lisinopril (15.86%) and hydrochlorothiazide (10.88%) were 
the most commonly prescribed medications within 60 days of initial disease 
identification. Inpatient (26.84%), emergency room (ER) (30.06%), office (99.78%), 
outpatient (99.81%) and pharmacy visits (93.65%) were calculated. Health care 
utilizations translated to the following health care expenses: inpatient ($9,841, 
SD $38,442), ER ($393, SD $1,042), office visit ($9,587, SD $13,035), outpatient 
($10,169, SD $13,599), and pharmacy costs ($1,771, SD $4,703). CONCLUSIONS: 
HCV treatment is complicated by the presence of comorbidities such as 
hypertension. Further analysis of complicated comorbid conditions is required to 
improve the overall burden of illness of HCV patients.  
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OBJECTIVES: To assess the population-level impact and cost-effectiveness of 
universal Hepatitis A vaccination of children in United States as recommended 
by Advisory Committee on Immunization Practices (ACIP) in 2006 compared with 
the prior ACIP regional policy of routine vaccination of children living in states 
with high hepatitis rates. METHODS: We developed a population-dynamic model 
of Hepatitis A to evaluate the public health- and economic- impacts of two-dose 
Hepatitis A vaccination of children 12 and 18 months of age. The dynamic model 
was fitted to Hepatitis A seroprevalence from the National Health and Nutrition 
Examination Survey (NHANES II and III) and reported incidence from the 
National Notifiable Diseases Surveillance System (1980–1995). We used a societal 
perspective and projected outcomes over the period 2006–2106 (a 100-year time 
horizon). Both costs and quality-adjusted life years (QALYs) were discounted at 
3% per year. RESULTS: Universal Hepatitis A vaccination prevented 144,375 
infections, 63,153 outpatient visits, 2,727 hospitalizations, and 96 deaths 
incrementally on an average annual basis when compared to the regional 
vaccination policy. Herd protection played an important role in reducing 
infections as it accounted for prevention of nearly 76% of deaths and 50% of 
outpatient visits and hospitalizations. Ignoring herd protection, vaccination 
prevented 90,845 infections, 34,353 outpatient visits, 1,438 hospitalizations, and 
23 deaths annually. Taking herd protection into account, universal vaccination 
was cost saving, whereas without it the ICER was $41,712/QALY. CONCLUSIONS: 
Universal two-dose vaccination of children led to significant reductions in 
Hepatitis A mortality and morbidity. Consequently, universal vaccination was 
cost saving compared with a regional vaccination policy. Herd protection effects 
of vaccination programs had a significant impact on hepatitis A mortality, 
morbidity, and cost-effectiveness ratios. Because of their ability to capture the 
natural phenomenon of herd protection, dynamic models have significant utility 
for economic evaluation of Hepatitis A vaccination programs.  
 
PIN50  
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OBJECTIVES: In 2011 PCV13 replaced PCV7 in Costa Rica’s National 
Immunization Program, however, continuation of the program is being evaluated 
based on considerations of cost-effectiveness. We evaluated the cost-
effectiveness of continuing universal PCV13 infant vaccination versus limiting 
vaccination to high-risk children. METHODS: We used a decision-analytic 
Markov model to assess the impact of alternative pediatric PCV13 vaccination 
strategies: universal versus targeted to high-risk children only. For the universal 
strategy, outcomes are assessed for the entire Costa Rican population to capture 
indirect (herd) effects that accrue in the unvaccinated individuals. The model 
was populated using Costa Rican epidemiologic data and estimates from other 
published sources. Estimates of PCV13 effectiveness were extrapolated from 
observed PCV7 data, using assumptions regarding serotype prevalence and 
PCV13 protection against 6 additional serotypes. Coverage was assumed to be 
the same for high-risk and the general population vaccination strategies. 
Outcome measures were incidence of invasive pneumococcal disease (IPD), 
pneumonia and acute otitis media (AOM); mortality, and net medical-care costs 
over 10 years from the societal perspective. RESULTS: Compared to no 
vaccination, the high-risk program would prevent 100 cases of IPD, 420 cases of 
hospitalized pneumonia (HP), 330 cases of non-hospitalized pneumonia (NHP), 
and 26,300 cases of AOM, and provide net savings of $460,000 over 10 years. 
Universal vaccination would prevent 2,200 cases of IPD, 14,800 cases of HP, 
24,500 cases of NHP, and 367,000 cases of AOM for net savings of $34.8 million. 
Compared to the high-risk program, universal vaccination would provide net 
savings of $34.3 million. Excluding indirect effects, universal vaccination results 
in ICERs of $4,400 and $5,600 per QALY gained compared with no vaccination 
and high-risk vaccination, respectively. CONCLUSIONS: Both high-risk and 
universal infant vaccination with PCV13 are cost-effective in Costa Rica; 
universal vaccination dominates both no vaccination and high risk vaccination 
due to indirect effects.  
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OBJECTIVES: Complicated skin and soft tissue infections (cSSTI) are commonly 
encountered in the community and nosocomial settings. Methicillin-resistant S. 
aureus (MRSA) has become the predominant pathogen in cSSTI raising health 
care costs and reducing positive health outcomes. The aim of this analysis is to 
estimate the cost-effectiveness of linezolid in the treatment of cSSTI in Chile 
from the private payer’s perspective. METHODS: A decision tree was built  
to estimate the incremental cost-effectiveness ratio (ICER) of linezolid (1200 
mg/day) compared with vancomycin (2 mg/day), daptomycin (350 mg/day) and 
tigecycline (100 mg/day). Within a time horizon of 28 days, the model simulates 
health outcomes and costs for all alternatives at the Provisional Health 
Institutions – ISAPRE. Only direct medical costs were considered. Effectiveness 
measures were: quality-adjusted life-year gained (QALY’s) and percentage of 
patients cured. Efficacy, safety and utility values were collected from literature 
review. Resource use and medical costs (drug acquisition, inpatient stay, health 
care professional visits, and lab tests) were taken from Chilean private 
institutions. Costs are expressed in 2012 US$. RESULTS: The total expected  
costs for per patient were: linezolid US$12,905.1, vancomycin US$13,039.9, 
daptomycin US$16,067.3 and tigecycline US$17,038.5. Treatment with linezolid 
was associated with a shorter length of stay at the intensive care unit (7 days on 
average) which reduced significant treatment costs due the likelihood of 
switching from intravenous to oral administration (5 days savings on average). 
Results for each alternative in terms of QALYs were: linezolid 0.063, vancomycin 
0.060, daptomycin 0.061 and tigecycline 0.059. The percentage of patients  
cured for each alternative was: linezolid 84.4%; vancomycin 74.7%; daptomycin 
78.1% and tigecycline 70.4%. Model result suggests that linezolid would be 
dominant compared to vancomycin, daptomycin and tigecycline. 
CONCLUSIONS: Despite its higher acquisition cost, linezolid would be a cost-
saving alternative in the treatment of cSSTI in the Chilean Provisional Health 
Institutions (ISAPRE).  
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OBJECTIVES: Complicated skin and skin structure infections (cSSSIs) are 
primarily caused by gram-positive bacteria, including Staphylococcus aureus and 
β-hemolytic streptococci. The impact of cSSSIs caused by Methicillin-resistant S. 
aureus (MRSA) has been associated with an increase in length of hospital stay 
and resource use. The aim of this analysis is to estimate the cost-effectiveness of 
linezolid in the treatment of cSSTI at the Chilean public setting. METHODS: A 
decision tree was built to estimate the incremental cost-effectiveness ratio of 
linezolid (1200 mg/day) compared to vancomycin (2 mg/day), daptomycin (350 
mg/day) and tigecycline (100 mg/day). The payer’s perspective (National Fund of 
Health – FONASA) was used, including inpatient medical costs only. The time 
horizon was 28 days. Effectiveness was measured with quality-adjusted life-year 
(QALY’s) and the percentage of patients cured. Efficacy, safety and utility values 
were retrieved from literature. Resource use and costs (drug acquisition, 
inpatient stay, health care professional visits, and lab tests) were taken from 
Chilean public health care institutions. Costs are expressed in 2012 USD. 
RESULTS: The total expected costs per patient were: linezolid US$3489.0, 
